Resonance Health Ltd

ASX:RHT

Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm is focused on the development and commercialization of technologies and services for the analysis of radiological images. The firm's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan uses Artificial Intelligence (AI) as an automated software medical device to determine liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The firm product HepaFat-Scan is a non-invasive MRI-based solution for measuring the volume fraction of fat in liver tissue. HepaFat-Scan is a medical device software, which is fully automated and uses Artificial Intelligence (AI) to assess liver fat. HepaFat-AI assesses and reports the volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF), and steatosis grade in individuals with suspected fatty liver disease.